Aditya Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aditya Sharma has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Fang
Department of Radiology, King's College Hospital NHS Foundation Trust, London, UK
1 shared publication - Christopher Stovin
Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
1 shared publication - Dominique Clement
Kings Health Partners, ENETS Centre of Excellence, Institute of Liver Studies, King’s College Hospital, London SE5 9RS, UK
1 shared publication Gisele Bentley
Department of Medicine, University of Cambridge, Cambridge, UK
1 shared publicationHasti Robbie
Department of Radiology, King's College Hospital NHS Foundation Trust, London, United Kingdom
1 shared publication- Ian B. Wilkinson
Division of Experimental Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
1 shared publication
Latest Publications
- 24 December 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 252, 108611
Limited clinical utility of annual chest radiographs in adults with cystic fibrosis: A 10-year observational study from a UK centre
- 24 December 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 252, 108611
Limited clinical utility of annual chest radiographs in adults with cystic fibrosis: A 10-year observational study from a UK centre
- Open Access
Ethnic differences in plasma aldosterone concentration and regulatory mechanisms of aldosterone: protocol for a systematic review and meta-analysis
Introduction Black ethnic cohorts, when compared with white cohorts, have disproportionately higher rates of essential hypertension and related complications. Ethnic differences in the renin-angiotensin-aldosterone system have been identified in black ethnic cohorts displaying a low-renin, salt-sensitive phenotype in comparison to white individuals. Studies have highlighted lower levels of aldosterone in black cohorts compared with white cohorts. However, when renin is considered, in the form of the aldosterone-renin ratio (ARR), the ARR is higher in black cohorts. The Framingham study highlighted that people in the upper quartile for baseline aldosterone were more likely to have a higher blood pressure and develop hypertension at 4 year follow-up. Therefore, the inappropriately suppressed aldosterone may be contributing to the ethnic differences in hypertension prevalence and prognosis. Methods and analysis Four databases will be searched (MEDLINE, Embase, Scopus and Cochrane Library) to identify eligible studies from database creation to August 2025. Two investigators will independently review the search results and document reasons for full-text exclusions. The main outcomes are to assess if there are ethnic differences in baseline aldosterone, baseline plasma renin activity (PRA) and ARR. We will also look at ethnic differences in regulatory mechanisms of aldosterone, such as serum potassium and 24 hour urinary electrolytes, that may explain the potential differences in aldosterone and ARR in black and white ethnic cohorts. Studies looking at normotensive and hypertensive individuals will be included. Studies in paediatric populations (Ethics and dissemination As this review will involve analysis of previously published data, ethical approval is not required. The results will be submitted to a peer-reviewed journal. PROSPERO registration number CRD420251025642.
Open AccessEthnic differences in plasma aldosterone concentration and regulatory mechanisms of aldosterone: protocol for a systematic review and meta-analysis
Introduction Black ethnic cohorts, when compared with white cohorts, have disproportionately higher rates of essential hypertension and related complications. Ethnic differences in the renin-angiotensin-aldosterone system have been identified in black ethnic cohorts displaying a low-renin, salt-sensitive phenotype in comparison to white individuals. Studies have highlighted lower levels of aldosterone in black cohorts compared with white cohorts. However, when renin is considered, in the form of the aldosterone-renin ratio (ARR), the ARR is higher in black cohorts. The Framingham study highlighted that people in the upper quartile for baseline aldosterone were more likely to have a higher blood pressure and develop hypertension at 4 year follow-up. Therefore, the inappropriately suppressed aldosterone may be contributing to the ethnic differences in hypertension prevalence and prognosis. Methods and analysis Four databases will be searched (MEDLINE, Embase, Scopus and Cochrane Library) to identify eligible studies from database creation to August 2025. Two investigators will independently review the search results and document reasons for full-text exclusions. The main outcomes are to assess if there are ethnic differences in baseline aldosterone, baseline plasma renin activity (PRA) and ARR. We will also look at ethnic differences in regulatory mechanisms of aldosterone, such as serum potassium and 24 hour urinary electrolytes, that may explain the potential differences in aldosterone and ARR in black and white ethnic cohorts. Studies looking at normotensive and hypertensive individuals will be included. Studies in paediatric populations (Ethics and dissemination As this review will involve analysis of previously published data, ethical approval is not required. The results will be submitted to a peer-reviewed journal. PROSPERO registration number CRD420251025642.
- Open Access
- 13 June 2024
- Published by Springer Nature in Current Oncology Reports
- Vol. 26 (9) , 1070-1084
Current Management of Neuroendocrine Tumour Liver Metastases
Purpose of review: This article aims to illustrate the current state of investigations and management of liver metastases in patients with Neuroendocrine Neoplasms. Neuroendocrine tumours (NETs) are rising in incidence globally and have become the second most prevalent gastrointestinal malignancy in UK and USA. Frequently, patients have metastatic disease at time of presentation. The liver is the most common site of metastases for gastro-enteropancreatic NETs. Characterisation of liver metastases with imaging is important to ensure disease is not under-staged. Recent Findings: Magnetic resonance imaging and positron emission tomography are now becoming standard of care for imaging liver metastases. There is an increasing armamentarium of therapies available for management of NETs and loco-regional therapy for liver metastases. The data supporting surgical and loco-regional therapy is reviewed with focus on role of liver transplantation. Summary: It is important to use appropriate imaging and classification of NET liver metastases. It is key that decisions regarding approach to treatment is undertaken in a multidisciplinary team and that individualised approaches are considered for management of patients with metastatic NETs.
- 13 June 2024
- Published by Springer Nature in Current Oncology Reports
- Vol. 26 (9) , 1070-1084
Open AccessCurrent Management of Neuroendocrine Tumour Liver Metastases
Purpose of review: This article aims to illustrate the current state of investigations and management of liver metastases in patients with Neuroendocrine Neoplasms. Neuroendocrine tumours (NETs) are rising in incidence globally and have become the second most prevalent gastrointestinal malignancy in UK and USA. Frequently, patients have metastatic disease at time of presentation. The liver is the most common site of metastases for gastro-enteropancreatic NETs. Characterisation of liver metastases with imaging is important to ensure disease is not under-staged. Recent Findings: Magnetic resonance imaging and positron emission tomography are now becoming standard of care for imaging liver metastases. There is an increasing armamentarium of therapies available for management of NETs and loco-regional therapy for liver metastases. The data supporting surgical and loco-regional therapy is reviewed with focus on role of liver transplantation. Summary: It is important to use appropriate imaging and classification of NET liver metastases. It is key that decisions regarding approach to treatment is undertaken in a multidisciplinary team and that individualised approaches are considered for management of patients with metastatic NETs.